Bristol-Myers Squibb (BMY) Declares $0.40 Quarterly Dividend; 2.6% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bristol-Myers Squibb (BMY) Reports 'Significant Skin Clearance' from Phase 2 Study of BMS-986165 in Patients with Moderate to Severe Plaque Psoriasis
September 12, 2018 5:59 AM EDTBristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase 2 study of BMS-986165, an investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis. Efficacy endpoints including 75% and 90% reduction in the Psoriasis Area and Severity Index (PASI 75, PASI 90) were achieved following 12 weeks of treatment with 3 mg daily of BMS-986165, with a... More
